114 related articles for article (PubMed ID: 12755580)
1. The vaccine crossroads.
Wilson JF
Ann Intern Med; 2003 May; 138(10):857-60. PubMed ID: 12755580
[No Abstract] [Full Text] [Related]
2. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public?
Levy E
Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481
[No Abstract] [Full Text] [Related]
3. Immunity for immunizations: tort liability, biodefense, and Bioshield II.
Mayer L
Stanford Law Rev; 2007 Apr; 59(6):1753-90. PubMed ID: 17593591
[No Abstract] [Full Text] [Related]
4. Key drivers behind the development of global vaccine market.
Gréco M
Vaccine; 2001 Feb; 19(13-14):1606-10. PubMed ID: 11166882
[No Abstract] [Full Text] [Related]
5. [Reasons for an injury compensation programme for adverse vaccine-related events in Spain].
Tuells J
Med Clin (Barc); 2013 Jun; 140(12):554-7. PubMed ID: 23540383
[No Abstract] [Full Text] [Related]
6. Vaccine candidates for poor nations are going to waste.
Kaslow DC; Black S; Bloom DE; Datla M; Salisbury D; Rappuoli R
Nature; 2018 Dec; 564(7736):337-339. PubMed ID: 30560957
[No Abstract] [Full Text] [Related]
7. Strengthening the supply of routinely administered vaccines in the United States: progress and problems--2005.
Klein JO; Helms CM
Clin Infect Dis; 2006 Mar; 42 Suppl 3():S145-50. PubMed ID: 16447138
[No Abstract] [Full Text] [Related]
8. Drug firm's legal action against government advisers is described as "intimidation".
Moynihan R
BMJ; 2010 Nov; 341():c6527. PubMed ID: 21084371
[No Abstract] [Full Text] [Related]
9. Informed consent and public health: are they compatible when it comes to vaccines?
Parmet WE
J Health Care Law Policy; 2005; 8(1):71-110. PubMed ID: 16538802
[No Abstract] [Full Text] [Related]
10. The fragility of the U.S. vaccine supply.
Sloan FA; Berman S; Rosenbaum S; Chalk RA; Giffin RB
N Engl J Med; 2004 Dec; 351(23):2443-7. PubMed ID: 15575064
[No Abstract] [Full Text] [Related]
11. Wyeth Pharmaceutical's perspective on vaccine production.
Stiles GL
Md Med; 2005; 6(1):22-3. PubMed ID: 15869103
[No Abstract] [Full Text] [Related]
12. The Cutter incident, 50 years later.
Offit PA
N Engl J Med; 2005 Apr; 352(14):1411-2. PubMed ID: 15814877
[No Abstract] [Full Text] [Related]
13. Wyeth responds to criticism.
Stiles GM
Md Med; 2005; 6(4):5, 7-8; author reply 8. PubMed ID: 16454430
[No Abstract] [Full Text] [Related]
14. Determinants of vaccine supply.
Natl Bur Econ Res Bull Aging Health; 2011; (3):2-3. PubMed ID: 22207917
[No Abstract] [Full Text] [Related]
15. Is there a future for vaccines?
Goldberg R
Expert Rev Vaccines; 2002 Jun; 1(1):1-3. PubMed ID: 12908504
[No Abstract] [Full Text] [Related]
16. Strengthening vaccination policies in Latin America: an evidence-based approach.
Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
[TBL] [Abstract][Full Text] [Related]
17. Veterinary vaccines in an economic and sociopolitical context. The viewpoint of the veterinary pharmaceutical industry.
Gug M
Dev Biol Stand; 1992; 79():31-6. PubMed ID: 1286762
[No Abstract] [Full Text] [Related]
18. Vaccine liability in the era of bioterrorism.
Mair JS; Mair M
Biosecur Bioterror; 2003; 1(3):169-84. PubMed ID: 15040195
[No Abstract] [Full Text] [Related]
19. The economics of vaccination from a global perspective: present and future. 2-3 December, 2004, Vaccines: all things considered, San Francisco, CA, USA.
Ehreth J
Expert Rev Vaccines; 2005 Feb; 4(1):19-21. PubMed ID: 15757469
[No Abstract] [Full Text] [Related]
20. Anticipating the impact of Bruesewitz v. Wyeth on Vaccine And Medical Countermeasure Injury Compensation And Availability.
Courtney B; Morhard R
Biosecur Bioterror; 2010 Dec; 8(4):315-20. PubMed ID: 21142760
[No Abstract] [Full Text] [Related]
[Next] [New Search]
